HomeMDG1 • ETR
add
MediGene AG
Previous close
€2.15
Day range
€2.13 - €2.19
Year range
€1.60 - €5.48
Market cap
30.02M EUR
Avg Volume
6.64K
P/E ratio
-
Dividend yield
-
Primary exchange
ETR
Market news
Financials
Income Statement
Revenue
Net income
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 1.46M | -6.00% |
Operating expense | 5.22M | -0.04% |
Net income | -4.08M | -0.57% |
Net profit margin | -280.10 | -6.99% |
Earnings per share | — | — |
EBITDA | -3.75M | 0.95% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 14.02M | -42.88% |
Total assets | 28.81M | -31.69% |
Total liabilities | 9.15M | -23.69% |
Total equity | 19.66M | — |
Shares outstanding | 14.74M | — |
Price to book | 1.61 | — |
Return on assets | — | — |
Return on capital | -44.32% | — |
Cash Flow
Net change in cash
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -4.08M | -0.57% |
Cash from operations | -3.54M | 11.77% |
Cash from investing | 3.85M | 201.29% |
Cash from financing | 2.36M | 2,998.77% |
Net change in cash | 2.68M | 194.29% |
Free cash flow | — | — |
About
Medigene AG is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers. The first product candidates are in clinical development. Wikipedia
Founded
1994
Headquarters
Website
Employees
87
